Letermovir

BreastfeedingPediatric
  • TRADE NAME: Prevymis (Merck Sharpe & Dohme)
  • INDICATIONS: Prophylaxis of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients of an allogeneic hematopoietic stem cell transplant.
  • CLASS: Antiviral, Viral terminase complex inhibitor
  • HALF-LIFE: 12 hours

FDA APPROVAL DATE: 11/08/2017

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Alfentanil, Amiodarone, Atorvastatin, Cyclosporine, Dihydroergotamine, Ergotamine, Fentanyl, Fluvastatin, Glyburide, Lovastatin, Midazolam, Omeprazole, Pantoprazole, Phenytoin, Pimozide, Pitavastatin, Pravastatin, Quinidine, Repaglinide, Rifampin, Rosiglitazone, Rosuvastatin, Simvastatin, Sirolimus, Tacrolimus, Voriconazole, Warfarin

PREGNANCY CATEGORY: N/A
No adequate human data available

Our database has 20 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN
CARDIOVASCULAR
CENTRAL NERVOUS SYSTEM
NEUROMUSCULAR/SKELETAL
GASTROINTESTINAL/HEPATIC
RESPIRATORY
ENDOCRINE/METABOLIC
HEMATOLOGIC


Page last updated 12/11/2017

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric